Incidence and Risk of QTc Interval Prolongation among Cancer Patients Treated with Vandetanib: A Systematic Review and Meta-analysis

Jiajie Zang; Shunquan Wu; Lei Tang; Xudong Xu; Jie Bai; Caicui Ding; Yue Chang; Long Yue; Enming Kang; Jia He

doi:10.1371/journal.pone.0030353

Loading metrics

Open Access

Peer-reviewed

Research Article

Incidence and Risk of QTc Interval Prolongation among Cancer Patients Treated with Vandetanib: A Systematic Review and Meta-analysis

Jiajie Zang ,

Contributed equally to this work with: Jiajie Zang, Shunquan Wu, Lei Tang

Affiliation Department of Health Statistics and Center of Evidence-based Medicine, Second Military Medical University, Shanghai, China
⨯
Shunquan Wu ,

Contributed equally to this work with: Jiajie Zang, Shunquan Wu, Lei Tang

Affiliation Department of Health Statistics and Center of Evidence-based Medicine, Second Military Medical University, Shanghai, China
⨯
Lei Tang ,

Contributed equally to this work with: Jiajie Zang, Shunquan Wu, Lei Tang

Affiliation Department of Health Statistics and Center of Evidence-based Medicine, Second Military Medical University, Shanghai, China
⨯
Xudong Xu,

Affiliation Cardiology Department, Changhai Hospital, Second Military Medical University, Shanghai, China
⨯
Jie Bai,

Affiliation Department of Geriatrics, Changhai Hospital, Second Military Medical University, Shanghai, China
⨯
Caicui Ding,

Affiliation Library of First Hospital, Peking University, Beijing, China
⨯
Yue Chang,

Affiliation Department of Endocrinology, Changhai Hospital, Second Military Medical University, Shanghai, China
⨯
Long Yue,

Affiliation Department of Endocrinology, Changhai Hospital, Second Military Medical University, Shanghai, China
⨯
Enming Kang,

Affiliation Department of Endocrinology, Changhai Hospital, Second Military Medical University, Shanghai, China
⨯
Jia He

* E-mail: hejia63@yahoo.com

Affiliation Department of Health Statistics and Center of Evidence-based Medicine, Second Military Medical University, Shanghai, China
⨯

Incidence and Risk of QTc Interval Prolongation among Cancer Patients Treated with Vandetanib: A Systematic Review and Meta-analysis

Jiajie Zang,
Shunquan Wu,
Lei Tang,
Xudong Xu,
Jie Bai,
Caicui Ding,
Yue Chang,
Long Yue,
Enming Kang,
Jia He

Published: February 17, 2012
https://doi.org/10.1371/journal.pone.0030353

Reader Comments (0)

Post a new comment on this article

Subject Areas
?

For more information about PLOS Subject Areas, click here.
We want your feedback. Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

Thyroid carcinoma
Is the Subject Area "Thyroid carcinoma" applicable to this article?

Thanks for your feedback.
Cancer treatment
Is the Subject Area "Cancer treatment" applicable to this article?

Thanks for your feedback.
Cancer epidemiology
Is the Subject Area "Cancer epidemiology" applicable to this article?

Thanks for your feedback.
Cancer risk factors
Is the Subject Area "Cancer risk factors" applicable to this article?

Thanks for your feedback.
Non-small cell lung cancer
Is the Subject Area "Non-small cell lung cancer" applicable to this article?

Thanks for your feedback.
Metaanalysis
Is the Subject Area "Metaanalysis" applicable to this article?

Thanks for your feedback.
Randomized controlled trials
Is the Subject Area "Randomized controlled trials" applicable to this article?

Thanks for your feedback.
Adverse events
Is the Subject Area "Adverse events" applicable to this article?

Thanks for your feedback.